Calcium

Standard Lithium Provides Comprehensive Results of Its Fully Optimized and Proven DLE Process

Retrieved on: 
Monday, November 20, 2023
Lithium, Dorado, Plant, DLE, Demonstration plant, Potassium, Magnesium, LSS, FRA, Calcium, Knowledge, SLI, Lithium chloride, Boron, Sodium

EL DORADO, Ark., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today shared detailed performance results from its Direct Lithium Extraction (DLE) process at its Demonstration Plant (Plant) near El Dorado, Arkansas.

Key Points: 
  • EL DORADO, Ark., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today shared detailed performance results from its Direct Lithium Extraction (DLE) process at its Demonstration Plant (Plant) near El Dorado, Arkansas.
  • Standard Lithium's Demonstration Plant is the only truly large-scale, continuously operating DLE plant in North America.
  • Both studies incorporate the LiPROTM LSS (DLE) process developed in collaboration with Koch Technology Solutions, LLC (“KTS”).
  • Lithium Recovery Efficiency: During a representative period of performance over July and August 2023, the LiPROTM LSS (DLE) process achieved an average lithium recovery of 96.1% from the continuous incoming brine flow.

Blue Diamond Introduces New Almond Breeze® Original Almond & Oat Blend

Retrieved on: 
Thursday, December 21, 2023
Retail, Supermarket, Food, Beverage, Diamond, Blue Diamond Growers, Multimedia, Glass, Taste, Cooking, Calcium, Eating, Innovation, Oat, Coffee, Flour

Blue Diamond, the world’s leading producer and marketer of almonds, announces a new addition to its selection of Almond Breeze products with the launch of Almond Breeze® Original Almond & Oat Blend .

Key Points: 
  • Blue Diamond, the world’s leading producer and marketer of almonds, announces a new addition to its selection of Almond Breeze products with the launch of Almond Breeze® Original Almond & Oat Blend .
  • View the full release here: https://www.businesswire.com/news/home/20231221353454/en/
    Blue Diamond Introduces New Almond Breeze® Original Almond & Oat Blend (Photo: Business Wire)
    Almond Breeze® Original Almond & Oat Blend combines the delicious flavor of the best California almonds with the creaminess of oat for a dreamy, dairy-free milk for any occasion.
  • “Almond Breeze® Original Almond & Oat Blend not only provides a great taste and creamy texture, but it is also a healthier alternative to other oatmilks.”
    A one-cup serving of Almond Breeze® Almond & Oat Blend contains only 4g total sugar, 45 calories, and 450mg of calcium, with 30% less sugar* and 50% fewer calories* than the national average of the leading original oatmilk brands.
  • Almond Breeze® Original Almond & Oat Blend will be available in grocery stores and major retailers beginning January 2024.

Christmas with "I Love Fruit & Veg from Europe": Gift a Citrus Tiramisu - a delightful and healthy holiday treat

Retrieved on: 
Saturday, December 23, 2023
European Commission, Immune system, Human, Friends, Magnesium, Chocolate, Calcium, Civil service commission, Folate, Phosphorus, Infection, Vitamin A, Christmas, Selenium

ROME, Dec. 23, 2023 /PRNewswire/ -- Christmas is just around the corner, bringing festive days and the best fruits of the season. With the project "I Love Fruit & Veg from Europe," promoted by the producer organizations Agritalia, A.O.A., La Deliziosa, Meridia, and Terra Orti, and co-financed by the European Commission, lunches and dinners can be rich, delicious, and healthy. Our gift under the Christmas tree this year is a Citrus Tiramisu, created by chef Pierpaolo Giorgio. It is the perfect conclusion to a Christmas meal featuring fruits from our holiday menus - oranges, lemons, and mandarins.

Key Points: 
  • ROME, Dec. 23, 2023 /PRNewswire/ -- Christmas is just around the corner, bringing festive days and the best fruits of the season.
  • With the project "I Love Fruit & Veg from Europe," promoted by the producer organizations Agritalia, A.O.A., La Deliziosa, Meridia, and Terra Orti, and co-financed by the European Commission, lunches and dinners can be rich, delicious, and healthy.
  • Our gift under the Christmas tree this year is a Citrus Tiramisu, created by chef Pierpaolo Giorgio.
  • It is the perfect conclusion to a Christmas meal featuring fruits from our holiday menus - oranges, lemons, and mandarins.

Global Biomaterials Manufacturer Himed Announces Leadership Transition in 2024

Retrieved on: 
Tuesday, December 19, 2023
Materials science, Calcium, Growth, Research, Johns Hopkins University, OLD, Environment

OLD BETHPAGE, N.Y., Dec. 19, 2023 /PRNewswire/ -- Himed ( www.himed.com ), a biomaterials manufacturer and pioneer in surface enhancements for medical implants in the dental and orthopedic markets, today announced a strategic leadership transition effective January 1, 2024.

Key Points: 
  • OLD BETHPAGE, N.Y., Dec. 19, 2023 /PRNewswire/ -- Himed ( www.himed.com ), a biomaterials manufacturer and pioneer in surface enhancements for medical implants in the dental and orthopedic markets, today announced a strategic leadership transition effective January 1, 2024.
  • Rosenblum's guidance has helped propel Himed to achieve remarkable milestones and solidified its position as an industry leader in biomaterials for medical devices, leading to his promotion.
  • His visionary leadership and deep understanding of biomaterials will undoubtedly drive Himed to new heights in the biomedical engineering field.
  • Ed has proven that if we stay focused on the needs of our customers, they will stay committed to Himed for decades."

Healthy Extracts Reports Third Quarter 2023 Results

Retrieved on: 
Tuesday, November 14, 2023
Meal, Sleep, Ultimate Brain, Brain, Acquisition, OTCQB, Calcium, Traction, Diaphragm, Sleep apnea, Marketing, GUT, Ageing, Growth, HEALTH, Rare-earth element, Video game, Life insurance, Insurance, Food delivery, Pharmaceutical industry, Mobile phone, Film industry, Q3

LAS VEGAS, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a platform for acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals that target select high-growth categories within the multibillion-dollar nutraceuticals market, reported results for the three and nine months ended September 30, 2023.

Key Points: 
  • LAS VEGAS, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a platform for acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals that target select high-growth categories within the multibillion-dollar nutraceuticals market, reported results for the three and nine months ended September 30, 2023.
  • Gross margin improved to 80.4% in the third quarter from 48.4% in the previous quarter due to a favorable shift to higher margin sales.
  • This compares to net loss of $170,000 or $(0.00) per basic and diluted share in the same year-ago quarter.
  • “In Q3, we continued to grow our top-line at a healthy double-digit pace as our product offerings, customer subscriptions, and distribution channels continued to expand,” commented Healthy Extracts president, Duke Pitts.

Tonix Pharmaceuticals Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorder

Retrieved on: 
Monday, November 13, 2023
Vitamin D, ASD, Tonix Pharmaceuticals, Osteoporosis, Woman, Adolescence, Safety, MGH, Calcium, Prevalence, Endocrinology, Bone density, IND, BOX, Spectrum, Division, Oxytocin, MPH, Massachusetts General Hospital, Pediatric endocrinology, Neurology, Autism spectrum, Biology, Hospital, Dietary supplement, Pediatrics

CHATHAM, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the first participant was enrolled in an investigator-initiated Phase 2 study of TNX-1900 (intranasal potentiated oxytocin) for improving bone health in children with autism spectrum disorder (ASD), named the BOX study, at Massachusetts General Hospital (MGH). The aim of this Department of Defense-funded study is to investigate the efficacy and safety of TNX-1900 as a novel therapeutic agent to increase bone density and improve bone structure and strength in children with ASD. Tonix is providing active drug and placebo for the BOX study as part of a drug donation agreement with MGH. MGH is the sponsor of the trial, which is being conducted under an investigator-initiated investigational new drug (IND) application.

Key Points: 
  • Tonix is providing active drug and placebo for the BOX study as part of a drug donation agreement with MGH.
  • MGH is the sponsor of the trial, which is being conducted under an investigator-initiated investigational new drug (IND) application.
  • “Low bone density in ASD is a serious problem,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.
  • A Z-score compares one’s bone density to the average bone density of age and gender matched controls.

United States Biochar Market Size, Share & Trends Analysis Report 2023-2030: Pyrolysis, Gasification, Agriculture, Animal Feed, Health & Beauty Products - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 13, 2023
Agriculture, Natural Resources, Climate change, Potassium, Calcium, Plant, Crop protection, State, Pyrolysis, Nitrogen, Public sector, USD, Farmer, Nutrient, Phosphorus, Animal feed, Erosion, Soil, Cosmetics, Industrialisation, Population density, Fertilizer, Magnesium

The "U.S. Biochar Market Size, Share & Trends Analysis Report By Technology (Pyrolysis, Gasification), By Application (Agriculture, Animal Feed, Health & Beauty Products), By State, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "U.S. Biochar Market Size, Share & Trends Analysis Report By Technology (Pyrolysis, Gasification), By Application (Agriculture, Animal Feed, Health & Beauty Products), By State, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Increased population density and human activities such as the rise in infrastructure and industrial development have led to the degradation of soil.
  • Some of the major causes of declined soil quality include deforestation, overgrazing, industrialization, increased agricultural activities, and natural calamities.
  • According to the Earthworm Foundation, in 2021, the United States faced a significant issue with soil erosion, which resulted in an estimated cost of $67.00 billion.

Vivasure Medical Announces First Patients Treated with PerQseal Elite Closure Device System

Retrieved on: 
Tuesday, December 12, 2023
Cardiology, Radiology, Surgery, General Health, Health, Medical Devices, Health Technology, Clinical Trials, TAVR, Safety, Calcium, Elite, ELITE, CAD, Aortic stenosis, Patient, Stenosis, EVAR, IDE, Trial of the century, TEVAR, Investigational device exemption

Vivasure Medical® , a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the first patient treated with PerQseal® Elite, the latest generation of the company’s fully absorbable large-hole closure system.

Key Points: 
  • Vivasure Medical® , a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the first patient treated with PerQseal® Elite, the latest generation of the company’s fully absorbable large-hole closure system.
  • Ph.D., at Erasmus University Hospital in Rotterdam, The Netherlands, as part of the company’s ELITE Study—a prospective, multi-center, single-arm clinical study evaluating the safety and efficacy of PerQseal Elite.
  • PerQseal Elite leverages the legacy PerQseal system’s excellent safety profile and ease of use.
  • The company continues to enroll patients for its Investigational Device Exemption (IDE) clinical study for PerQseal and PerQseal+ in the United States.

Maple From Canada Will Pay Americans Back If They Add Pure Maple Syrup to Their Breakfast Orders

Retrieved on: 
Monday, December 4, 2023
Retail, Restaurant, Bar, Forest Products, Agriculture, Natural Resources, Food, Beverage, Meal, Farmer, Copper, Research, Condiment, Manganese, Multimedia, Calcium, Riboflavin, Maple syrup, Maple

Maple from Canada , a brand of the Québec Maple Syrup Producers who represents over 13,300 maple farmers, is launching an initiative called Bill the Maple after discovering that Americans often have to pay extra to enjoy pure maple syrup at their favourite breakfast restaurants.

Key Points: 
  • Maple from Canada , a brand of the Québec Maple Syrup Producers who represents over 13,300 maple farmers, is launching an initiative called Bill the Maple after discovering that Americans often have to pay extra to enjoy pure maple syrup at their favourite breakfast restaurants.
  • According to the research conducted by SMS Research Advisors for Maple from Canada (2022), over half of the American respondents misidentified table syrup as maple syrup.
  • “In Canada, pure maple syrup is everywhere and truly is one of our national treasures,” shared David Marino, Promotion and Market Development Director at Maple from Canada.
  • To learn more about the Bill The Maple initiative and how to get your pure maple syrup refunded visit billthemaple.com .

Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.

Retrieved on: 
Friday, November 17, 2023
FDA, Pharmaceutical, Health, Medicine, Vomiting, Digoxin, Osteoporosis, Woman, Urine, Antares, NYSE, Bone disease, Calcium, Spine, Prednisone, Constipation, Allergy, History, IQVIA, Patient, Arthralgia, Medication, TEVA, Fracture, Muscle weakness, System, Blood, Tongue, Vitamin, Bone tumor, Nausea, Kidney, Pain, Swelling, Osteosarcoma, Skin, Rat, TASE, Injection, Face, Blood pressure, Generic drug, Dietary supplement, Pharmaceutical industry, Vaccine, Birth control, Injection moulding, Medical imaging, Poultry farming, Phosphorus, Teriparatide, Teva

Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the approval of a generic version of Forteo®1, in the United States.

Key Points: 
  • Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the approval of a generic version of Forteo®1, in the United States.
  • Currently, 1 in 12 generic prescriptions dispensed in the U.S. is filled with a Teva generic product.
  • Teva’s generic equivalent of Forteo® (teriparatide injection) utilizes the Antares Pharma, Inc. multi-dose pen device.
  • Teriparatide injection can lessen the chance of broken bones (fractures) in the spine and other bones in postmenopausal women with osteoporosis.